TAS6417/CLN-081 is a pan-mutation-selective EGFR tyrosine kinase inhibitor with a broad spectrum of preclinical activity against clinically relevant EGFR mutations - Udagawa, H; Hasako, S; Ohashi, A (Mol Cancer Res, 2019)